Bioabsorbable Materials News
-
Cordis-X Makes Strategic Investment in Adient Medical, Developer of First Fully Absorbable Inferior Vena Cava (IVC) Filter
Cordis-X today announced an $11.5 million Series F investment in Adient Medical, maker of a next-generation absorbable inferior vena cava (IVC) filter that provides protection against pulmonary embolisms (PE). The device is designed to avoid well-documented risks of perforation, migration, fracture, and thrombosis currently associated with IVC filters. Such safety issues have been the focus of ...
-
First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic ...
-
Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced it has received CE Mark approval for the company’s PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union. The Contour CE approval expands the portfolio of PROPEL products ...
-
Expand Post-Market Study Evaluating Longer-Term Outcomes of PROPEL Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it began the process of initiating the Company’s EXPAND Clinical Study by successfully registering on ClinicalTrials.gov (NCT04858802). EXPAND is a prospective, randomized, single-blind, intra-patient controlled, ...
-
CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid Services (CMS) published an average selling price (ASP) for the Company’s SINUVA sinus implant, providing predictability, transparency, and confidence of reimbursement for ...
-
Steven Damon Appointed Chief Executive Officer of Micron Biomedical, A Novel Vaccine and Therapeutic Technology Company
ATLANTA, June 1, 2020 /PRNewswire/ — Micron Biomedical, Inc., an Atlanta based biopharmaceutical company, has appointed industry veteran, Steven Damon, as the company CEO. Mr. Damon will lead Micron on a path to rapid development and commercialization of Micron’s proprietary dissolvable, microneedle-based technology, a novel technology designed for simple, safe and effective ...
-
Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical Electrophysiology
Santa Clara, Calif. - October 30, 2019 - Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that positive results from the AMBULATE pivotal study demonstrating the safety and efficacy of the company’s VASCADE® MVP Venous Vascular Closure System compared to manual compression were published online in the Journal of the American College of Cardiology: ...
-
Cardiva Medical Announces FDA Approval of the VASCADE MVP Vascular Closure System for Multi-Site Vessel Closure Following Electrophysiology Procedures
VASCADE MVP is the first vessel closure technology designed for electrophysiology procedures – and proven by electrophysiology physicians in a multi-center, randomized, controlled clinical trial. Potential procedures include cardiac ablation and left atrial appendage closure among others. Greater than 400,000 patients per year in the United States may benefit – with procedures ...
-
Cardiva Medical Announces Positive Results of the AMBULATE Pivotal Study Evaluating the VASCADE MVP System Compared to Manual Compression for Multi-Vessel Closure Following Electrophysiology Procedures
The AMBULATE pivotal study met its primary efficacy endpoint. The median time to patients getting on their feet following arrhythmia ablation procedures was reduced by 3.9 hours. AMBULATE demonstrated that patients in the VASCADE MVP arm had significantly improved patient satisfaction and a significant reduction in the post-procedure use of opioid pain medications. Late-breaking results were ...
-
16 Mar Moximed Closes Oversubscribed $50MM Financing Round
Hayward, CA, USA, March 15, 2017 – Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA), announced today an oversubscribed Series C round of $50MM with new investors Advent Life Sciences and Future Fund joining existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, and Vertex ...
By Moximed Inc
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you